Metagenomi Therapeutics, Inc. Overview
Pro stress-test →Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company is advancing in vivo gene-editing therapies toward clinical development.
Strategic Profile
Pro stress-test →The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products. Its lead program MGX-001 targets hemophilia A with clinical development targeted for 2026.
Competitive Landscape
Pro stress-test →Metagenomi competes in the emerging in vivo gene editing space against companies like Caribou Biosciences, Prime Medicine, and Sangamo Therapeutics. The company differentiates through its comprehensive metagenomics-derived toolbox covering multiple editing modalities (nucleases, base editors, prime editors, integration systems). Partnerships with Ionis and Affini-T expand addressable market and reduce execution risk.
Industry Context
Metagenomi Therapeutics, Inc. operates in Genetic Medicines & Gene Editing.
Key facts
Founded: 2016 · Headquarters: Emeryville, California · Revenue: $52.3M (2024) · Market cap: $64.2M